Cargando…

How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better

Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient’s risk of adverse ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddel, Helen K, Foxley, Gloria J, Davis, Sharon R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427634/
https://www.ncbi.nlm.nih.gov/pubmed/36110163
http://dx.doi.org/10.18773/austprescr.2022.033
_version_ 1784778950171426816
author Reddel, Helen K
Foxley, Gloria J
Davis, Sharon R
author_facet Reddel, Helen K
Foxley, Gloria J
Davis, Sharon R
author_sort Reddel, Helen K
collection PubMed
description Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient’s risk of adverse effects. They may also increase the patient’s out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.
format Online
Article
Text
id pubmed-9427634
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-94276342022-09-14 How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better Reddel, Helen K Foxley, Gloria J Davis, Sharon R Aust Prescr Article Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient’s risk of adverse effects. They may also increase the patient’s out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely. NPS MedicineWise 2022-08-01 2022-08 /pmc/articles/PMC9427634/ /pubmed/36110163 http://dx.doi.org/10.18773/austprescr.2022.033 Text en (c) NPS MedicineWise https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Article
Reddel, Helen K
Foxley, Gloria J
Davis, Sharon R
How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
title How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
title_full How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
title_fullStr How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
title_full_unstemmed How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
title_short How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
title_sort how to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427634/
https://www.ncbi.nlm.nih.gov/pubmed/36110163
http://dx.doi.org/10.18773/austprescr.2022.033
work_keys_str_mv AT reddelhelenk howtostepdownasthmapreventertreatmentinpatientswithwellcontrolledasthmamoreisnotalwaysbetter
AT foxleygloriaj howtostepdownasthmapreventertreatmentinpatientswithwellcontrolledasthmamoreisnotalwaysbetter
AT davissharonr howtostepdownasthmapreventertreatmentinpatientswithwellcontrolledasthmamoreisnotalwaysbetter